Act Capital Management, LLC Enlivex Therapeutics Ltd. Transaction History
Act Capital Management, LLC
- $72.5 Million
- Q3 2022
A detailed history of Act Capital Management, LLC transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Act Capital Management, LLC holds 15,000 shares of ENLV stock, worth $19,050. This represents 0.09% of its overall portfolio holdings.
Number of Shares
15,000
Previous 15,000
-0.0%
Holding current value
$19,050
Previous $68,000
5.88%
% of portfolio
0.09%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding ENLV
# of Institutions
22Shares Held
2.1MCall Options Held
16.1KPut Options Held
3.4K-
Armistice Capital, LLC New York, NY1.7MShares$2.16 Million0.03% of portfolio
-
Morgan Stanley New York, NY245KShares$311,0120.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny71.7KShares$91,0450.0% of portfolio
-
Xtx Topco LTD London, X024.8KShares$31,5210.0% of portfolio
-
Goldman Sachs Group Inc New York, NY11.4KShares$14,5140.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $23.4M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...